Pharmacologic options for the treatment and management of food allergy

Aaron K. Kobernick, Jeffrey Chambliss, A. Wesley Burks

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Food allergy affects approximately 5% of adults and 8% of children in developed countries, and there is currently no cure. Current pharmacologic management is limited to using intramuscular epinephrine or oral antihistamines in response to food allergen exposure. Recent trials have examined the efficacy and safety of subcutaneous, oral, sublingual, and epicutaneous immunotherapy, with varying levels of efficacy and safety demonstrated. Bacterial adjuvants, use of anti-IgE monoclonal antibodies, and Chinese herbal formulations represent exciting potential for development of future pharmacotherapeutic agents. Ultimately, immunotherapy may be a viable option for patients with food allergy, although efficacy and safety are likely to be less than ideal.

Original languageEnglish (US)
Pages (from-to)623-633
Number of pages11
JournalExpert Review of Clinical Pharmacology
Issue number5
StatePublished - Sep 3 2015
Externally publishedYes


  • Adjuvant
  • Allergy
  • Anaphylaxis
  • Egg
  • Epicutaneous
  • Food
  • Immunotherapy
  • Milk
  • Multifood
  • Omalizumab
  • Oral
  • Peanut
  • Probiotic
  • Sublingual

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacologic options for the treatment and management of food allergy'. Together they form a unique fingerprint.

Cite this